GILD Stock Price, Chart, Stats & News

Gilead Sciences, Inc.
Save
GILD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 80.80% |
Operating margin | 37.37% |
Pretax margin | 33.28% |
Net margin | 28.90% |
Effective tax rate | 13.13% |
ROA | 14.42% |
ROE | 41.01% |
D/E | 1.09x |
Interest coverage ratio | 10.73x |
GILD valuation
P/E | 15.41x |
P/S | 5.66x |
P/B | 7.37x |
P/CF | 16.64x |
P/FCF | 17.63x |
P/OCF | 16.64x |
PEG | 3.87x |
EV multiple | 11.60x |
About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
Similar securities
Based on sector and market capitalization
Report issue











